1-12 of 12
Zhihua Yao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-PD-1 Antibody (Tislelizumab) Combined with R-CHOP for the Treatment of Previously Untreated Primary Mediastinal B-Cell Lymphoma: A Prospective Phase II Study

Mei Wu, Lin Zhu, Shan Li, Tuerde Jiaerbao, Shanshan Wang, Xiao Liang, Xin Hu, Li Guo, Abulikemujiang Adili, Xianmusiya Maimaitirexiati, Ruirui Ren, Zhihua Yao, Shuna Yao, Shujuan Wen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6236.
https://doi.org/10.1182/blood-2023-182504
Published: 2023
Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6234.
https://doi.org/10.1182/blood-2023-180413
Published: 2023
Journal Articles

Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up

Jianqiu Wu, Fei Li, Zhi-Jun Wuxiao, Weiyan Tang, Yue Teng, Yanyan Liu, Han Chu, Zhiya Wu, Yiwen Shen, Fancong Kong, Zhihua Yao, Weilun Zhou, Jifeng Feng
Journal: Blood
Blood (2023) 142 (Supplement 1): 6265.
https://doi.org/10.1182/blood-2023-181831
Published: 2023
Journal Articles

Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study

Zheng Yan, Shuna Yao, Shuang Zhao, Haiying Wang, Junfeng Chu, Yuanlin Xu, Jiuyang Zhang, Lina Zhang, Quande Lin, Lijie Liang, Ping Wang, Wenyong Li, Xiaolu Teng, Zhihua Yao, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3075.
https://doi.org/10.1182/blood-2023-185902
Published: 2023
Journal Articles

Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma

Shuna Yao, Zhihua Yao, Zheng Yan, Haiying Wang, Junfeng Chu, Shuang Zhao, Xinyang Zhao, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1758.
https://doi.org/10.1182/blood-2023-189345
Published: 2023
Journal Articles

Phase II Clinical Trial of R-CHOP Combined with Lenalidomide in the First-Line Treatment for Patients with High Risk Diffuse Large B Cell Lymphoma

Shuang Zhao, Jiuyang Zhang, Zheng Yan, Yuanlin Xu, Zhihua Yao, Junfeng Chu, Shuna Yao, Haiying Wang, Wenping Zhou, Xufeng Luo, Peipei Zhang, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6237.
https://doi.org/10.1182/blood-2023-185955
Published: 2023
Journal Articles

Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

Shuang Zhao, Yanyan Liu, Zhihua Yao, Zheng Yan, Shuna Yao, Junfeng Chu, Haiying Wang, Jiuyang Zhang, Peipei Zhang, Wenping Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 6579–6580.
https://doi.org/10.1182/blood-2022-166829
Published: 2022
Journal Articles

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

Jun Ma, Li Zhiming, Wei Xu, Yao Liu, Weili Zhao, Zhihua Yao, Kaiyang Ding, Yudan Wu, Hong Liu, Wenyu Li, Yirong Jiang, Li'e Lin, Zhigang Peng, Zhimin Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 12130–12132.
https://doi.org/10.1182/blood-2022-166137
Published: 2022
Journal Articles

Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma

Zhihua Yao, Zheng Yan, Shuna Yao, Haiying Wang, Junfeng Chu, Shuang Zhao, Jie Ma, Bing Wei, Jiawen Zheng, Quande Lin, Zheng Xu, Xinyang Zhao, Yanyan Liu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3767–3768.
https://doi.org/10.1182/blood-2022-165944
Published: 2022
Journal Articles

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Hui-qiang Huang, Zengjun Li, Gang Cheng, Gao Yan, Zhihua Yao, Guifang Zhang, Xiaoguang Wang, Zhengxiang Han, Yong Chen, Haijiao Yan, Weie Zheng, Jun Yan, Yulan Gu, Zhangxia Ren, Rusen Zhao, Ningling Zhang, Jun Ma
Journal: Blood
Blood (2021) 138 (Supplement 1): 4569.
https://doi.org/10.1182/blood-2021-149884
Published: 2021
Journal Articles

A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort

Jianqiu Wu, Yanyan Liu, Li Fei, Zhi-Jun Wuxiao, Fancong Kong, Zhihua Yao, Weilun Zhou, Jifeng Feng
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142553
Published: 2020
Journal Articles

An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL

Yun Mai, J. Jessica Yu, Boris Bartholdy, Zijun Y. Xu-Monette, Esther E. Knapp, Fei Yuan, Hongshan Chen, B. Belinda Ding, Zhihua Yao, Bhaskar Das, Yiyu Zou, Ken He Young, Samir Parekh, B. Hilda Ye
Journal: Blood
Blood (2016) 128 (24): 2797–2807.
https://doi.org/10.1182/blood-2016-03-705814
Published: 2016
Includes: Supplemental data